Studies how ravulizumab affects people with neuromyelitis optica spectrum disorder
Observes how ravulizumab affects adults with neuromyelitis optica spectrum disorder over time.
Plain-language title generated from the registry record
Registry title: Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder
Key facts
- Where
- Dallas, United StatesSee the site
Where in United States
- UT Southwestern Medical CenterDallas, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Texas Southwestern Medical Center
- Trial code
- NCT06398158
- Record updated
- 13 October 2026
- Original description
This is an observational study to:Read full original descriptionShow less
Clinical and Radiological Outcomes in People With Aquaporin-4 IgG Positive Neuromyelitis Optica Spectrum Disorder Treated With Ravulizumab
This is an observational study to:
* evaluate the on-treatment clinical performance of ravulizumab in relation to the pre-treatment time period (time period prior to exposure), * enhance knowledge regarding conventional MRI outcomes in people with NMOSD treated with ravulizumab, * identify factors suggestive of subclinical disease progression through conventional MRI sequences, * determine if treatment with ravulizumab, impacts longitudinal 3D conformational MRI measures at the dorsal medulla and other regions of the CNS, and * identify biomarkers (e.g., serum neurofilament light chain (sNfL), conventional and novel MRI markers, etc.) related to disease activity.
Inclusion: Signed informed consent available prior to conduct of any study associated activities; Men and women > 18 years of age; Aquaporin-4 IgG positive people with neuromyelitis optica spectrum disorder treated with commercially available ravulizumab in a manner consistent with the approved indication; Expanded Disability Status Scale score of <7.0.
Exclusion: Individuals previously exposed to eculizumab with treatment discontinuation due to lack of effective disease control (i.e., clinical relapse or demonstration of MRI advancement after 12 weeks of sustained treatment exposure); Unresolved meningococcal disease; History of an active infection; Existing participation in neuromyelitis optical spectrum disorder interventional clinical studies; Individuals who are intolerant to MRI; Pregnant or lactating women.